SBP GROUP (01177.HK): Boehringer deal worth up to US$7bn
- The deal covers six preclinical ADC and TCE assets, five from LaNova Medicines and one from Beijing Tide Pharmaceutical.
- The Group gets US$358 million upfront plus up to US$7 billion in milestones and double-digit royalties on future sales.
NewTimeSpace News: On 4 November 2026, Sino Biopharmaceutical Limited (stock code: 01177) said it signed a strategic option and licence agreement with Boehringer Ingelheim, its second oncology collaboration with the partner, covering six preclinical assets in antibody-drug conjugates (ADC) and T-cell engagers (TCE), five from wholly-owned unit LaNova Medicines and one from Beijing Tide Pharmaceutical.
The Group will lead early development through global Phase I trials. After agreed clinical milestones, Boehringer Ingelheim may exercise options for exclusive development, manufacturing and commercialisation rights to four assets worldwide excluding mainland China, Hong Kong and Macao, and to the other two globally. The Group will receive US$358 million in upfront and near-term payments, up to US$7 billion in option, development, regulatory and commercial milestones, and double-digit royalties.
- SBP GROUP (01177.HK): Two Hepatitis B Drugs Granted CDE Breakthrough Therapy Status
- SBP GROUP (01177.HK): TQB2102 Data at ESMO; Phase III Breast Cancer Median PFS 16.4 Months
- SBP GROUP (01177.HK): TQC2731 Phase III fully enrolled in CRSwNP
- SBP GROUP (01177.HK): TQ-A3334, Bepirovirsen Data Picked for AASLD
- SBP GROUP (01177.HK): TQC3721 Phase III completes enrolment
